Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Solomon SD, Claggett BL, Miao ZM, Diaz R, Felker GM, McMurray JJV, Metra M, Corbalan R, Filippatos G, Goudev AR, Mareev V, Serpytis P, Suter T, Yilmaz MB, Zannad F, Kupfer S, Heitner SB, Malik FI, Teerlink JR. Solomon SD, et al. Among authors: kupfer s. Eur Heart J. 2022 Jun 14;43(23):2212-2220. doi: 10.1093/eurheartj/ehac144. Eur Heart J. 2022. PMID: 35325102 Clinical Trial.
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB; EXAMINE Investigators. Zannad F, et al. Among authors: kupfer s. Lancet. 2015 May 23;385(9982):2067-76. doi: 10.1016/S0140-6736(14)62225-X. Epub 2015 Mar 10. Lancet. 2015. PMID: 25765696 Clinical Trial.
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, Cushman WC, Mehta CR, Bakris GL, Zannad F, White WB; EXAMINE Investigators. Shimada YJ, et al. Among authors: kupfer s. Am Heart J. 2016 May;175:18-27. doi: 10.1016/j.ahj.2016.01.011. Epub 2016 Jan 23. Am Heart J. 2016. PMID: 27179720 Clinical Trial.
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso García Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G. Zannad F, et al. Among authors: kupfer s. Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):200-5. doi: 10.1093/ehjcvp/pvw007. Epub 2016 Apr 3. Eur Heart J Cardiovasc Pharmacother. 2016. PMID: 27418973 Free PMC article. Review.
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S; EXAMINE Investigators. White WB, et al. Among authors: kupfer s. Hypertension. 2016 Sep;68(3):606-13. doi: 10.1161/HYPERTENSIONAHA.116.07797. Epub 2016 Aug 1. Hypertension. 2016. PMID: 27480840 Clinical Trial.
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP; EXAMINE Investigators. Heller SR, et al. Among authors: kupfer s. Diabetes Obes Metab. 2017 May;19(5):664-671. doi: 10.1111/dom.12871. Epub 2017 Feb 27. Diabetes Obes Metab. 2017. PMID: 28058763 Free PMC article. Clinical Trial.
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA. Cavender MA, et al. Among authors: kupfer s. Circulation. 2017 May 16;135(20):1911-1921. doi: 10.1161/CIRCULATIONAHA.116.024632. Epub 2017 Feb 28. Circulation. 2017. PMID: 28246236 Clinical Trial.
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
Metra M, Pagnesi M, Claggett BL, Díaz R, Felker GM, McMurray JJV, Solomon SD, Bonderman D, Fang JC, Fonseca C, Goncalvesova E, Howlett JG, Li J, O'Meara E, Miao ZM, Abbasi SA, Heitner SB, Kupfer S, Malik FI, Teerlink JR. Metra M, et al. Among authors: kupfer s. Eur Heart J. 2022 Dec 21;43(48):5006-5016. doi: 10.1093/eurheartj/ehac293. Eur Heart J. 2022. PMID: 35675469 Free PMC article.
349 results